1. Introduction of Minocycline hydrochloride
Minocycline hydrochloride is one kind of crystalline yellow powder. The IUPAC Name of this chemical is (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide hydrochloride. Besides, the Product Category of Minocycline hydrochloride is Antibacterial;Antibiotic Explorer;Intermediates & Fine Chemicals;Pharmaceuticals;Peptide Synthesis/Antibiotics. In addition, Minocycline hydrochloride Classification Code is Anti-Bacterial Agents; Anti-Infective Agents; Antibacterial; Drug / Therapeutic Agent; Human Data; Natural Product. Minocycline hydrochloride can soluble in water.

2. Properties of Minocycline hydrochloride
Physical properties about Minocycline hydrochloride are:
(1)H-Bond Donor: 6; (2)H-Bond Acceptor: 9; (3)Molecular Formula: C₂₃H₂₇N₃O₇.ClH; (4)Molecular Weight: 493.94; (5)EINECS: 237-099-7; (6)Flash Point: 445.4 °C; (7)Enthalpy of Vaporization: 123.88 kJ/mol; (8)Boiling Point: 812.8 °C at 760 mmHg; (9)Vapour Pressure: 6.33E-28 mmHg at 25 °C; (10)Melting point: 205-210 °C (dec); (11)Storage tempreture: 2-8 °C; (12)Appearance: Yellow crystalline powder.

3. Structure Descriptors of Minocycline hydrochloride
(1)InChI: InChI=1S/C23H27N3O7.ClH/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28;/h5-6,9,11,17,27-28,31,33H,7-8H2,1-4H3,(H2,24,32);1H/t9-,11-,17-,23-;/m0./s1
(2)InChIKey: WTJXVDPDEQKTCV-VQAITOIOSA-N
(3)Canonical SMILES: CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C.Cl
(4)Isomeric SMILES: CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C.Cl
(5)Smiles: Cl.[C@@H]12[C@](C(=C3[C@H](C2)Cc2c(C3=O)c(ccc2N(C)C)O)O)(C(=O)C(=C([C@H]1N(C)C)O)C(=O)N)O

4. Toxicity of Minocycline hydrochloride

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
human	TDLo	oral	14286ug/kg/10 (14.286mg/kg)	LUNGS, THORAX, OR RESPIRATION: RESPIRATORY OBSTRUCTION LUNGS, THORAX, OR RESPIRATION: DYSPNEA SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	Archives of Internal Medicine. Vol. 154, Pg. 1633, 1994.
man	TDLo	intravenous	2857ug/kg (2.857mg/kg)	LUNGS, THORAX, OR RESPIRATION: "FIBROSIS, FOCAL (PNEUMOCONIOSIS)" LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	Internal Medicine. Vol. 33, Pg. 177, 1994.
man	TDLo	oral	11429ug/kg/4D (11.429mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	Archives of Dermatology. Vol. 123, Pg. 18, 1987.
man	TDLo	oral	3893mg/kg/4Y- (3893mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	Archives of Dermatology. Vol. 122, Pg. 17, 1986.
mouse	LD50	intraperitoneal	299mg/kg (299mg/kg)		Drugs in Japan Vol. 6, Pg. 811, 1982.
mouse	LD50	intravenous	154mg/kg (154mg/kg)		Drugs in Japan Vol. 6, Pg. 811, 1982.
mouse	LD50	oral	3600mg/kg (3600mg/kg)		Drugs in Japan Vol. 6, Pg. 811, 1982.
mouse	LD50	subcutaneous	2290mg/kg (2290mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 21, Pg. 319, 1990.
mouse	LDLo	parenteral	620mg/kg (620mg/kg)		Chemotherapy Vol. 24, Pg. 17, 1978.
rat	LD50	intraperitoneal	331mg/kg (331mg/kg)		Drugs in Japan Vol. 6, Pg. 811, 1982.
rat	LD50	intravenous	164mg/kg (164mg/kg)		Drugs in Japan Vol. 6, Pg. 811, 1982.
rat	LD50	oral	2380mg/kg (2380mg/kg)		Drugs in Japan Vol. 6, Pg. 811, 1982.
rat	LD50	subcutaneous	1700mg/kg (1700mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 21, Pg. 319, 1990.
women	TDLo	oral	42mg/kg/3W-I (42mg/kg)	BLOOD: AGRANULOCYTOSIS BLOOD: OTHER CHANGES MUSCULOSKELETAL: JOINTS	Archives of Internal Medicine. Vol. 154, Pg. 1983, 1994.

5. Safety information of Minocycline hydrochloride
Hazard Codes: Xi
Risk Statements: 36/37/38
R36/37/38:Irritating to eyes, respiratory system and skin.
Safety Statements: 26-36 
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. 
S36:Wear suitable protective clothing.
RIDADR: 3249
WGK Germany: 3
RTECS: QI7630500
HazardClass: 6.1(b)
PackingGroup：  III
Risk Statements： Irritating to the eyes；Irritating to the respiratory system；Irritating to the skin
Safety Statements： Wear suitable protective clothing
Poison by intravenous and intraperitoneal routes. Moderately toxic by ingestion and parenteral routes. Human systemic effects: dermatitis, eye effects, increased body temperature. When heated to decomposition it emits toxic fumes of NO_x and HCl.

6. Uses of Minocycline hydrochloride
Minocycline hydrochloride (CAS NO.13614-98-7) is primarily used to treat acne and other skin infections as well as lyme disease as the one pill twice daily 100 mg dosage is far easier for patients than the four times a day required with tetracycline or oxytetracycline. It may be used to treat certain strains of MRSA infection and disease caused by drug resistant Acinetobacter. And it is mainly used as second generation tetracycline antibiotic and  antibacterial.

7. Production of Minocycline hydrochloride
You can get the Minocycline hydrochloride by using 6-demethyl chlortetracycline as raw material with the azo the salt derivatives law or esterification prepared minocycline.